Isocitrate dehydrogenase wild-type GBM is a form of highly aggressive brain tumour accounting for 49.1% of primary malignant brain tumours with less than 7% of patients surviving after 5 years post-diagnosis (Ostrom et al., 2021). Here, IDH3A is linked to brain neoplasm.